Sanofi's genetic disorder drug shows mixed results in late-stage trials [Yahoo! Finance]
Sanofi - American Depositary Shares (SNY)
US:NYSE Investor Relations:
sanofi.com/en/investors
Company Research
Source: Yahoo! Finance
promise in a late-stage study of patients with ?a type of Gaucher disease, but failed to meet the main goal in ?a separate trial. The oral drug, venglustat, was being tested in patients with Fabry disease and type 3 Gaucher disease. Both ?inherited conditions are caused by enzyme deficiencies that lead to the accumulation of toxic substances in the body. Previous failures in trials of patients with Parkinson's disease and a type of acute kidney disease have prompted Sanofi to prioritize testing the drug in rare genetic disorders, where its mechanism of ?blocking the buildup of harmful fatty ?molecules has yielded promising early-stage results. Analysts have not projected future sales for venglustat as market expectations for its success remain low. Sanofi is banking on ?its late-stage pipeline and recent acquisitions to help drive sales growth in the next decade, after the top-selling eczema and asthma drug Dupixent it shares with Regeneron loses exclusivity. Sanofi's bet co
Show less
Read more
Impact Snapshot
Event Time:
SNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SNY alerts
High impacting Sanofi - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
SNY
News
- Is Sanofi (ENXTPA:SAN) Offering Value After Recent Share Price Weakness [Yahoo! Finance]Yahoo! Finance
- Why OpenAI's drug royalties deal won't work [Yahoo! Finance]Yahoo! Finance
- Pfizer sets sights on R&D strategy amid modest FY25 results [Yahoo! Finance]Yahoo! Finance
- GSK Advances Respiratory And Vaccine Growth With Key RSV And Asthma Moves [Yahoo! Finance]Yahoo! Finance
- Latent TB Diagnostics Research Report 2026: Global Market Analysis and Forecasts 2025-2029 by Assay, Risk Factor, and Lab/Place with Executive and Consultant Guides [Yahoo! Finance]Yahoo! Finance
SNY
Sec Filings
- 2/6/26 - Form 6-K
- 2/5/26 - Form S-8
- 1/29/26 - Form 6-K
- SNY's page on the SEC website